compounded semaglutide and tirzepatide vs. for Weight Loss Compounded Semaglutide & Tirzepatide 2025:

Its unusual stability, including reported stability in acidic environments, makes BPC-157 distinct among research peptides and a frequent subject of gastrointestinal, musculoskeletal, vascular, and organ-protection research

It was originally made available to treat type 2 diabetes

At 3 and 12 months post-index, 1.5 mg dulaglutide was the most common dosage formulation (81% and 79%, respectively), with dispensation of dulaglutide 3.0 mg and 4.5 mg less common throughout follow-up

GLP-1 agonists, not the only drugs to address more than one indication This is not the first time that a drug has been used for several indications

Long-term efficacy Effective in maintaining and improving hair count with consistent use